No Detail Found!

Efficacy of azathioprine and methotrexate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s)
Shamza Mehreen Department of Neurology, King Edward Medical University/ Mayo Hospital,Lahore,Pakistan
Sadaf Iftikhar Department of Neurology, King Edward Medical University/ Mayo Hospital,Lahore,Pakistan
Ali Muhammad Department of Neurology, King Edward Medical University/ Mayo Hospital,Lahore,Pakistan
Rana Aatif Siddique Department of General Medicine and Gastroenterology, Shahida Islam Medical and Dental College,Lodhran,Pakistan
Saman Shahid Department of Sciences & Humanities, National University of Computer & Emerging Sciences (NUCES),FAST Lahore,Pakistan
Abstract
The study examined the efficacy of various immunosuppressants in patients with chronic inflammatory demyelinating polyneuropathy. We compared the efficacy of Azathioprine and Methotrexate in the treatment of CIDP. Patients of either gender aged > 18 years having chronic polyneuropathy progressive for at least 8 weeks having no serum para protein or any genetic abnormality and fulfilling the Koski criteria. To measure the efficacy, Overall Neuropathy Limitation Scale (ONLS) was used. Group 1 was treated with a combination of oral steroids i.e., Prednisolone and Azathioprine while group 2 was treated with a combination of Prednisolone and Methotrexate. ONLS was statistically insignificant in the patient groups (AZA versus MTX) at the beginning of the therapy (from 1-3 months) in both groups. However, in the 4th month, the AZA group performed better than the MTX group. At the 12th month, the mean ONLS score of the patients in the AZA group was 3.69, while the mean ONLS score of the patients in the MTX group was 5.30 (p-value=0.001). We concluded that Azathioprine was more efficacious as compared to Methotrexate in the treatment of CIDP based on ONLS and should be considered as a first-line immunosuppressant in the treatment of CIDP in low-income countries like Pakistan.
Publication Details
Page(s) 1361-1365
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S4, Year: 2023

Request the full text from PASTIC

Keywords
Prednisolone, Azathioprine (AZA), overall neuropathy limitation scale (ONLS), chronic inflammatory demyelinating polyneuropathy (CIPD), Koski criteria, methotrexate (MTX)
References
Castle D,Robertson NP D .2019 .Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol., 266 : 2338-2340.
Díaz-Manera J,Rojas-García R,Gallardo E,Illa I .2009 .Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient. Muscle & Nerve, 39 : 386-388.
Dimachkie MM,Barohn RJ .2013 .Chronic inflammatory demyelinating polyneuropathy. Curr. Treat. Options Neurol, 15(3) : 350-66.
Dyck PJ,O'Brien P,Swanson C,Low P,Daube J .1985 .Combined azathioprine and prednisone in chronic inflammatory‐demyelinating polyneuropathy. Neurology, 35(8) : 1173-1176.
Dyck PJB,Tracy JA .2018 .History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clinic Proceedings, Elsevier., : .
Gorson KC .2012 .An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther. Adv. Neurol. Disord., 5(6) : 359-373.
Graham RC,Hughes RA .2006 .A modified peripheral neuropathy scale: The overall neuropathy limitations scale. J. Neurol. Neurosurg. Psychiatry, 77(8) : 973-976.
Hughes RA,Donofrio P,Bril V,Dalakas MC,Deng C,Hanna K,Hartung HP,Latov N,Merkies ISJ .2008 .Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial. Lancet Neurol, 7(2) : 136-144.
Hughes RA,Swan AV .2004 .Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane. Database Syst. Rev., : CD003280.
Hung SK,Hiew FL,Viswanathan S,Puvanarajah S S .2018 .Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression. , 23(3) : 183-189.
Iijima M,Koike H,Sobue G H .2013 .Therapeutic strategy for CIDP (chronic inflammatory demyelinating polyneuropathy). Nihon Rinsho, 71(5) : 855-860.
Kuitwaard K and van Doorn PA .2009 .Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs, 69(8) : 987-1001.
Mahdi-Rogers M,Brassington R,Gunn AA,van Doorn PA,Hughes RA .2017 .Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane. Database Syst. Rev., 5(5) : Cd003280.
Mahdi-Rogers M,van Doorn PA,Hughes RA .2013 .Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane. Database Syst. Rev., 14(6) : Cd003280.
AL and Gimigliano F Oaklander .2019 .Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? A cochrane overview summary with commentary. Neuro Rehabilitation, 44(4) : 609-612.
0

Citations

0

Downloads

129

Views